Cargando…
Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
Cachexia, and particularly the loss of metabolically active lean tissue, leads to increased morbidity and mortality in affected patients. An impairment of strength and functional status is usually associated with cachexia. A variety of anabolic and appetite-stimulating agents have been studied in pa...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177042/ https://www.ncbi.nlm.nih.gov/pubmed/21966638 http://dx.doi.org/10.1007/s13539-011-0040-8 |
_version_ | 1782212266446290944 |
---|---|
author | Thum, Thomas Springer, Jochen |
author_facet | Thum, Thomas Springer, Jochen |
author_sort | Thum, Thomas |
collection | PubMed |
description | Cachexia, and particularly the loss of metabolically active lean tissue, leads to increased morbidity and mortality in affected patients. An impairment of strength and functional status is usually associated with cachexia. A variety of anabolic and appetite-stimulating agents have been studied in patients with cachexia caused by various underlying diseases. Overall, these studies have demonstrated that treatment can increase body weight and/or lean body mass. However, these therapies may have severe side effects, particularly when utilizing testosterone and related anabolic steroids targeting the androgen receptor. These side effects include cardiovascular problems, prostate hyperplasia and cancer in men, as well as virilization in women. |
format | Online Article Text |
id | pubmed-3177042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-31770422011-09-30 Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! Thum, Thomas Springer, Jochen J Cachexia Sarcopenia Muscle Editorial Cachexia, and particularly the loss of metabolically active lean tissue, leads to increased morbidity and mortality in affected patients. An impairment of strength and functional status is usually associated with cachexia. A variety of anabolic and appetite-stimulating agents have been studied in patients with cachexia caused by various underlying diseases. Overall, these studies have demonstrated that treatment can increase body weight and/or lean body mass. However, these therapies may have severe side effects, particularly when utilizing testosterone and related anabolic steroids targeting the androgen receptor. These side effects include cardiovascular problems, prostate hyperplasia and cancer in men, as well as virilization in women. Springer-Verlag 2011-09-21 2011-09 /pmc/articles/PMC3177042/ /pubmed/21966638 http://dx.doi.org/10.1007/s13539-011-0040-8 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Editorial Thum, Thomas Springer, Jochen Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
title | Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
title_full | Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
title_fullStr | Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
title_full_unstemmed | Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
title_short | Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
title_sort | breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177042/ https://www.ncbi.nlm.nih.gov/pubmed/21966638 http://dx.doi.org/10.1007/s13539-011-0040-8 |
work_keys_str_mv | AT thumthomas breakthroughincachexiatreatmentthroughanovelselectiveandrogenreceptormodulator AT springerjochen breakthroughincachexiatreatmentthroughanovelselectiveandrogenreceptormodulator |